Atrial Fibrillation - Market Insights & Drugs Sales Forecast to 2020 for the $12.5 Billion Market - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Atrial Fibrillation - Market Insights & Drugs Sales Forecast (AF) - 2020" report to their offering.

The Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.

Scope of the Report:

- Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management and current treatment options.

- Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.

- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.

- It also provides Atrial fibrillation (AF) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

Key Topics Covered:

Executive Summary

Chapter 1 Anticoagulants Introduction

Chapter 2 Atrial Fibrillation

Chapter 3 Key Marketed Anticoagulants

Chapter 4 Anticoagulants Market Assessment by AF

Chapter 5 United States Anticoagulants Market Assessment by AF

Chapter 6 Europe 5 Anticoagulants Market Assessment by AF

Chapter 7 Japan Anticoagulants Market Assessment by AF

Chapter 8 Xarelto (rivaroxaban) Drug Profile

Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile

Chapter 10 Eliquis(Apixaban) Drug Profile

Chapter 11 Savaysa (edoxaban tosylate) Drug Profile

Chapter 12 Market Drivers and Constraints

Companies Mentioned

- Bayer

- Boehringer Ingelheim

- Bristol-Myers Squib

- Daiichi Sankyo

- Janssen Pharmaceutica

For more information visit http://www.researchandmarkets.com/research/qwvqcq/atrial

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals, Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals, Cardiovascular Drugs